The collaboration enables scientists to bypass months of empirical laboratory work. In tests conducted with the University of Pennsylvania, 97% of antibiotic peptides generated by EDEN proved active against WHO-designated priority pathogens. Notably, one candidate, EDEN-7, demonstrated efficacy comparable to last-line antibiotics against multidrug-resistant Acinetobacter baumannii, even without further iterative engineering.
In section Releases
Basecamp Research links EDEN models to Anthropic’s Claude Science
Drug-resistant infections claim nearly 5 million lives annually, but a new integration between Basecamp Research and Anthropic aims to turn the tide. By bringing the EDEN biological design models into the Claude Science workbench, researchers can now generate and prioritize antibiotic and vaccine candidates through simple conversational prompts in minutes.
Beyond antibiotic discovery, the platform streamlines vaccine development by identifying proteins most likely to trigger immune responses. This capability leverages BaseData, a massive biological dataset sourced from over 200 global locations, ranging from deep-sea sediment to polar ice. Unlike models trained on narrow, well-studied organisms, EDEN utilizes a repository containing over 10 billion new genes. Basecamp Research plans to expand this foundation 100-fold via the Trillion Gene Atlas project, supported by partners including NVIDIA and PacBio, while maintaining strict data provenance and benefit-sharing agreements with the source nations.
Comments (0)
No comments yet. Be the first!